Skip to main content

Table 3 Health economic outcomes by infection type and pathogen (unadjusted)a–c

From: An open-label, pragmatic, randomized controlled clinical trial to evaluate the comparative effectiveness of daptomycin versus vancomycin for the treatment of complicated skin and skin structure infection

  Abscess Cellulitis Wound
By infection typed Daptomycin Vancomycin Daptomycin Vancomycin Daptomycin Vancomycin
(n = 40) (n = 42) (n = 54) (n = 44) (n = 17) (n = 16)
 IRLOS, hours, mean (SD) 83.8 (53.8) 102.1 (75.4) 97.3 (61.5) 80.2 (43.5) 94.4 (63.4) 109.0 (59.0)
 Total LOS, hours, mean (SD) 94.8 (102.2) 105.6 (75.2) 101.7 (64.4) 85.1 (56.6) 103.0 (58.9) 139.3 (94.3)
 Total inpatient cost, 2012 US$, mean (SD)a 9515 (8501) 9432 (5955) 9871 (5805) 7415 (4750) 9814 (5927) 13,101 (7025)
  Staphylococcus aureus e MRSA MSSA
By pathogen Daptomycin Vancomycin Daptomycin Vancomycin Daptomycin Vancomycin
(n = 58) (n = 43) (n = 39) (n = 27) (n = 14) (n = 10)
 IRLOS, hours, mean (SD) 98.4 (64.5) 101.2 (69.4) 98.5 (67.0) 85.9 (51.8) 84.5 (43.6) 136.2 (95.5)
 Total LOS, hours, mean (SD) 109.0 (95.9) 105.4 (69.3) 111.3 (108.5) 92.3 (53.7) 93.0 (54.2) 136.2 (95.5)
 Total inpatient cost, 2012 US$, mean (SD)a 10,508 (8109) 9604 (5691) 10,692 (9171) 8854 (4119) 8967 (4084) 11,308 (8345)
  1. IRLOS infection-related length of stay, LOS length of stay, MRSA methicillin-resistant Staphylococcus aureus, MSSA methicillin-susceptible Staphylococcus aureus, SD standard deviation, WAC wholesale acquisition cost
  2. aMultivariate analysis sample of 115 daptomycin and 106 vancomycin patients
  3. bWAC cost estimates using “waste” algorithm
  4. cThe P value was nonsignificant for all comparisons between daptomycin and vancomycin
  5. dFour daptomycin and four vancomycin patients had other infection types
  6. eIncludes known S. aureus infection for those patients with a culture; please note 5 daptomycin and 6 vancomycin patients were dropped from the MRSA/MSSA subgroup analyses mostly due to missing data